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The mechanism of lithium's therapeutic action remains obscure, hindering the discovery of safer
treatments for bipolar disorder. Lithium can act as an inhibitor of the kinase GSK3a/b, which in turn
negatively regulates b-catenin, a co-activator of LEF1/TCF transcription factors. However, unclear is
whether therapeutic levels of lithium activate b-catenin in the brain, and whether this activation could
have a therapeutic signiﬁcance. To address this issue we chronically treated mice with lithium. Although
the level of non-phospho-b-catenin increased in all of the brain areas examined, b-catenin translocated
into cellular nuclei only in the thalamus. Similar results were obtained when thalamic and cortical
neurons were treated with a therapeutically relevant concentration of lithium in vitro. We tested if
TCF7L2, a member of LEF1/TCF family that is highly expressed in the thalamus, facilitated the activation
of b-catenin. Silencing of Tcf7l2 in thalamic neurons prevented b-catenin from entering the nucleus, even
when the cells were treated with lithium. Conversely, when Tcf7l2 was ectopically expressed in cortical
neurons, b-catenin shifted to the nucleus, and lithium augmented this process. Lastly, we silenced tcf7l2
in zebraﬁsh and exposed them to lithium for 3 days, to evaluate whether TCF7L2 is involved in the
behavioral response. Lithium decreased the dark-induced activity of control zebraﬁsh, whereas the ac-
tivity of zebraﬁsh with tcf7l2 knockdown was unaltered. We conclude that therapeutic levels of lithium
activate b-catenin selectively in thalamic neurons. This effect is determined by the presence of TCF7L2,
and potentially contributes to the therapeutic response.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
An estimated 1.5e6% of the adult population is affected by bi-
polar disorder (BD), characterized by alternations between
depressive and manic episodes of different lengths and intensities
(Hilty et al., 2006). The ﬁrst-line therapy to stabilize mood is
lithium due to its prophylactic and acute effectiveness, although the
mechanism of its therapeutic action is still under investigation
(Freland and Beaulieu, 2012). Unfortunately, the margin between
these beneﬁcial effects and severe toxicity is small, thusentre of New Technologies,
, 02-097 Warsaw, Poland.
isniewska).
Ltd. This is an open access article unecessitating investigations of new treatments (Kinahan et al.,
2014). To discover targets for alternative mood stabilizers, the
molecular mechanisms that underlie the therapeutic effects of
lithium must be ascertained.
Three direct targets of lithium ions have been extensively
studied: inositol monophosphate phosphatase (IMPA1 and IMPA2),
glycogen synthase kinase 3 (GSK3a and -b), and the signaling
complex of AKT kinase, b-arrestin 2, and protein phosphatase 2A
(PP2A) (Beaulieu and Caron, 2008; O'Brien and Klein, 2009).
Lithium inhibits IMPA and GSK3 by competing with magnesium
ions, which is a cofactor for these enzymes (Ryves and Harwood,
2001). The inhibition of IMPA leads to reduction of available
inositol and downstream targets of inositol cycle, which in turn
decrease the release of calcium, diacylglycerol activation and pro-
tein kinase C activity (Berridge, 1984). In the case of the AKT/b-
arrestin 2/PP2A complex, lithium prevents its formation and thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2012). AKT inhibits GSK3 by phosphorylating it at serine 9/21,
providing an additional mechanism of the lithium-dependent in-
hibition of GSK3.
Studies with genetically modiﬁed mice have supported the hy-
pothesis that GSK3 is a target of lithium in the treatment of BD.
GSK3b haploinsufﬁciency or the deletion of GSK3b in D2R-
expressing neurons mimicked lithium treatment in induced
models of depression and mania (O'Brien et al., 2004; Urs et al.,
2012), whereas the ectopic expression of a constitutively active
GSK3b mutant or overexpression of GSK3b reversed lithium-
sensitive behavior (O'Brien et al., 2011; Prickaerts et al., 2006).
However, one issue is whether the therapeutic concentrations of
lithium in serum and the brain (i.e., 0.5e1.5 mM) (Beaulieu et al.,
2008; Guelen et al., 1992; Oruch et al., 2014; Soares et al., 2001)
can actually exert an inhibitory effect on GSK3 because it requires
3e10 times higher levels to see the effect in cell-based assays
(Kremer et al., 2011). Furthermore, a question emerges, what are
the downstream therapeutic targets of lithium and GSK3?
One of the targets of GSK3 is b-catenin, a mediator of the ca-
nonical Wnt signaling pathway. GSK3 phosphorylates b-catenin at
serine 33/37 in a destruction complex that also comprises adeno-
matous polyposis coli (APC) and AXIN1/2.When phosphorylated, b-
catenin can be degraded via the proteasome pathway. The stimu-
lation of cells with a canonical WNT ligand leads to rearrangement
of the complex and the release of non-phosphorylated b-catenin,
followed by the translocation of b-catenin to the nucleus where it
acts in tandem with lymphoid enhancer-binding factor 1/T-cell
factors (LEF1/TCF) to regulate gene transcription (Archbold et al.,
2012). In mammals, the TCF/LEF family includes LEF1, TCF7,
TCF7L1 and TCF7L2. The mechanism of the cytoplasmic-nuclear
redistribution of b-catenin is not fully understood. Some studies
implicated b-catenin binding partners, particularly TCF/LEF tran-
scription factors, in b-catenin nuclear-cytoplasmic shuttling or
retention (Henderson, 2000; Henderson et al., 2002; Huber et al.,
1996; Jamieson et al., 2011; Krieghoff et al., 2006; Rosin-Arbesfeld
et al., 2003; Schmitz et al., 2011; Tolwinski and Wieschaus, 2001;
Wiechens and Fagotto, 2001). The physiological implications and
possible regulatory role of this mechanism have not yet been
conﬁrmed.
b-catenin is critically involved in embryonic patterning and
stem cell proliferation and differentiation, including nervous sys-
tem development (Bengoa-Vergniory and Kypta, 2015; Braun et al.,
2003; Hsu et al., 2015; Lie et al., 2005; Luo and Huang, 2016; Nouri
et al., 2015; Schafer et al., 2015; Zechner et al., 2003). The nuclear
localization of b-catenin is also observed in neurons in the adult
brain but only in the thalamus and medial habenula in the dien-
cephalon, and tectum in the midbrain (Misztal et al., 2011; Nagalski
et al., 2013; Wisniewska et al., 2010). TCF7L2 is also speciﬁcally
expressed in these brain regions (Nagalski et al., 2013). The precise
role of b-catenin and TCF7L2 in adult brain function is still elusive
(Wisniewska, 2013), nevertheless recent evidence suggests that
TCF7L2/b-catenin play a role in the thalamus in determining the
ﬁnal identity of thalamic neurons (Nagalski et al., 2016) and driving
expression of genes that regulate neuronal excitability
(Wisniewska et al., 2010, 2012). b-catenin could play a role in the
regulation of anxiety-related behavior. For example, transgenic
mice that express a stabilized form of b-catenin in neurons
exhibited a decrease in immobility time in the forced swim test and
attenuation of amphetamine-induced hyperlocomotion (Gould
et al., 2007).
In the present study, we used a mouse and zebraﬁsh model of
chronic lithium treatment and primary neuronal cultures to
determine whether lithium, at concentrations that are considered
to be therapeutic in humans, can activate b-catenin (i.e., induce itsstabilization and nuclear translocation) in the brain. Although
lithium at a high concentration (10 mM) activated b-catenin in
different types of neurons, b-catenin shifted to the nucleus at a
therapeutically relevant concentration (1 mM) only in thalamic
neurons, both in vivo and in vitro. This selective action of lithium
appeared to occur through the TCF7L2-dependent nuclear accu-
mulation of b-catenin, which operates in thalamic neurons. The
silencing of tcf7l2 in zebraﬁsh antagonized the effect of lithium on
dark-induced locomotion, suggesting the involvement of TCF7L2 in
the behavioral response to lithium treatment.
2. Materials and methods
2.1. Animal handling
C57BL/6 mice (male, 8e9 weeks old) were housed under stan-
dard conditions with food and water available ad libitum. Breeding
zebraﬁsh (Danio rerio) of the ABxTL line were maintained at 28 C
on a 14 h light/10 h dark cycle (Brand et al., 2002). The embryos
were staged according to Kimmel et al. (1995). All of the experi-
ments were approved by the Polish local Ethical Committee No.1 in
Warsaw (approval no. 275/2012).
2.2. Lithium administration in mice
The mice were given LiCl by intraperitoneal injections (2 mmol/
kg body weight in a volume of 100 ml) for 14 days or in drinking
water (600 mg/L) for 7e11 days. Control mice were injected with
physiological saline or given pure drinking water, respectively. Af-
ter the mice were sacriﬁced by cervical translocation, blood sam-
ples were immediately collected from the heart.
2.3. Lithium measurement
Lithium ions concentrations in murine serum and brain sam-
ples, and in whole zebraﬁsh were measured by inductively coupled
plasma mass spectrometry (ICP-MS) in the Central Chemical Lab-
oratory of the Polish Geological Institute.
2.4. Total protein extraction and subcellular fractionation
For total protein extracts brain fragments were sectioned, and
the tissue was immediately homogenized in cold lysis buffer
(20 mM Tris [pH 6.8], 0.1 M NaCl, 2 mM EDTA [pH 8.0], 10% glycerol,
1% TritonX-100, 0.5 mM DTT, 1 mM PMSF, and protease and phos-
phatase inhibitors) with a Potter-Elvehjem homogenizer. For sub-
cellular protein fractions brain fragments were immediately
homogenized in buffer A (10 mM HEPES [pH 7.9], 1.5 mM MgCl2,
10 mM NaCl, 0.5 mM DTT, 0.5 mM PMSF, and protease inhibitors)
with a Potter-Elvehjem homogenizer followed by a passage
through a 26-gauge needle and then centrifuged at 1000g for
10 min. Afterward, the supernatants and pellets were processed
separately. The supernatants were centrifuged at 100,000g for 1 h
to separate cytosolic and membrane fractions. Supernatant/cyto-
solic fractions were collected, and pellets/membranes were resus-
pended in buffer M (10mMTris [pH 7.4],1mMEDTA [pH 8.0],1mM
EGTA [pH 8.0], 150 mM NaCl, 0.5% Triton X-100, 0.1% NP-40, and
protease and phosphatase inhibitors). In parallel, the 1000g pel-
lets, representing cell nuclei and debris, were resuspended in 3 vol
of buffer B (20 mM HEPES [pH 7.9], 1.5 mM MgCl2, 600 mM NaCl,
0.5 mM DTT, 0.2 mM EDTA [pH 8.0], 0.5 mM PMSF, and protease
inhibitors) and incubated for 30 min with gentle shaking to release
nuclear proteins. The samples were then centrifuged at 25,000g
for 30min, and the collected supernatants were further centrifuged
at 100,000g for 30 min to remove debris and membrane
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of the steps of the isolation procedure were performed at 4 C.
2.5. Semi-quantitative Western blot
Concentrations of proteins in the extracts were measured using
the Bradford assay (Bio-Rad), and equal amounts (10e20 mg) were
separated on 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis gels. The following primary antibodies were used:
rabbit anti-b-catenin (1:500; Santa Cruz Biotechnology), rabbit
anti-non-phospho (active) b-catenin (Ser33/37/Thr41, 1:500; Cell
Signaling), mouse anti-NeuN (1:1000; Millipore), rabbit anti-
GAPDH (1:250; Santa Cruz Biotechnology), mouse anti-Pan-
cadherin (1:1000; Abcam), and rabbit anti-HSP90 (1:1000; Enzo
Life Sciences). Two types of secondary antibodies were used,
depending on a subsequent visualization method: antibodies
coupled with ﬂuorophores IRDye 800CW or IRDye 680RD
(1:10,000; LI-COR Biosciences) for the Odyssey Infrared Imaging
System (LI-COR Biosciences), and antibodies coupled with horse-
radish peroxidase (HRP; 1:10,000; Sigma Aldrich) for the Image-
Quant LAS 4000 system (GE Healthcare Life Sciences). In the latter
case, the chemiluminescent reaction with luminol, cumaric acid,
and hydrogen peroxide was performed with membranes stained
with primary and secondary antibodies. The intensity or density of
the detected bands was quantiﬁed using Image Studio 1.1 software
(LI-COR Biosciences) or ImageQuant TL 7.0 software (GE Healthcare
Life Sciences), respectively.
2.6. Primary neuronal cultures
Dissociated primary thalamic and cortical cultures were pre-
pared from embryonic day 19 rat brains and cultured according to
procedures described previously (Misztal et al., 2011). The Polish
local Ethical Committee No. 1 in Warsaw approved the procedure.
To reduce glial cell growth in thalamic cultures, 2.5 mM AraC was
added to themedium for 24 h on the day after seeding. The neurons
were grown in Neurobasal medium supplemented with B27
(Gibco), 0.5 mM glutamine, 12.5 mM glutamate, and penicillin/
streptomycin (Sigma Aldrich). All of the cultures were maintained
at 37 C in a humidiﬁed atmosphere with 5% CO2.
2.7. Cell transfection
Thalamic neurons on 4 days in vitro (4 DIV) were transfectedwith
0.4 mg empty pCGplasmid plus 0.1 mg greenﬂuorescent protein (GFP)
expression plasmid pCMV-GFP and 0.25 mg Tcf7l2-speciﬁc short-
hairpin RNA (shRNA) expression plasmid per well. The shRNA se-
quences were the following: shRNA 1 (5-CACCTCCGCACTTACCAGC-
3), shRNA 2 (5-CTCCGAAAGTTTCCGAGAT-3), and shRNA 3 (5-
CACACATCGTTTCGAACAA-3). These sequences were designed using
siRNA Selection Server (Yuan et al., 2004). The control shRNA (5-
CCTAAGGTTAAGTCGCCCT-3) did not match any rodent mRNA
sequence (Karalayetal., 2011).All of theoligonucleotideswerecloned
into pSUPER plasmids. Neurobasal medium (50 ml) and 1.5 ml of Lip-
ofectamine 2000 (Invitrogen) were added to the DNA, gently mixed,
and incubated for 25 min at room temperature. The media from the
cells were collected and replaced by media without antibiotics and
without glutamate. The DNA mixtures were then added to the cells
for 4h.Afterward, the cellswerewashedandkept in themediumthat
was collected before transfection. After 72 h, the cell cultures were
ﬁxed.
2.8. Cell transduction
Recombinant adenoviruses were prepared using the AdEasyAdenoviral Vector System (Agilent Technologies). For GFP and
TCF7L2 overexpression, pShuttle vector wasmodiﬁed by inserting a
truncated RSV promoter, woodchuck post-transcriptional regula-
tory element (WPRE), and SV-40 polyadenylation signal sequence
as previously described (Boulos et al., 2006). TCF7L2-S3 isoform
cDNA was subcloned from pCG-TCF7L2-S3 plasmid into a modiﬁed
pShuttle vector. Viruses were generated from pShuttle vectors us-
ing a standard procedure described elsewhere (Luo et al., 2007),
followed by puriﬁcation using the Vivapure AdenoPACK 20 kit
(Sartorius) and titration with the AdEasy Viral Titer Kit (Agilent
Technologies), yielding approximately 1010 infection units/ml. The
viral stocks were maintained at 80 C before use. On 4 DIV of the
neuronal culture, half of the culture media was removed, and pu-
riﬁed virus was added to each well at 100 MOI (multiplicity of
infection) and incubated for 6 h at 37 C. The virus solution was
then removed and replaced by fresh neuronal culture media. After
72 h, the cells were treated with 10 mM lithium chloride or PBS for
6 h and then ﬁxed.
2.9. Cell treatment
For proteasome inhibition, 10 mM MG132 (Sigma Aldrich) or
dimethylsulfoxide (DMSO; as a control) were added for 14 h before
ﬁxation to 7 DIV thalamic neurons. For GSK3 inhibition, 1 and
10 mM LiCl or PBS (as a control) were added for 6 h before ﬁxation.
For Wnt activation, WNT3A (50 ng/ml) was added for 6 h before
ﬁxation.
2.10. Immunoﬂuorescent cell staining
The immunoﬂuorescence analysis was performed as described
previously (Misztal et al., 2011). Brieﬂy, the cells were incubated
overnight with rabbit anti-b-catenin antibody (1:250; Santa Cruz
Biotechnology) in a humidiﬁed chamber and then for 1.5 h at room
temperature with mouse anti-TCF7L2 antibody (1:1000; EMD
Millipore). The secondary antibodies [anti-mouse and anti-rabbit
IgG coupled with AlexaFluor 488, 568, or 674 (Invitrogen, Molec-
ular Probes, Eugene)] were applied for 45min at room temperature.
All of the antibodies were diluted in 2% bovine serum albumin. The
images were acquired using a Zeiss LSM5 Exciter confocal micro-
scope. The levels of nuclear and cytoplasmic b-catenin and TCF7L2
(mean grey values for ﬂuorescence intensity) were measured using
ImageJ software followed by manually selecting intracellular re-
gions of interest (ROIs). Equal contrast and brightness enhance-
ment were used for the images shown in the ﬁgures.
2.11. Morpholino injection
The tcf7l2 Morpholino (MO, Gene Tools) was injected into one-
cell stage wild type (WT) embryos in the concentration of 4 ng/
ml. The Morpholino binds to the ﬁrst exon and ﬁrst intron (50-
CTTATTTGTCACTTACCTCGGAATC-30). WT embryos injected with
water were used as a control.
2.12. Exposure of zebraﬁsh larvae to lithium
Two days after the morpholino injections, the zebraﬁsh larvae
received 5 mM NaCl (control), or 1 and 5 mM LiCl dissolved in
standard E3 medium for zebraﬁsh embryos. The plates were
maintained at 28.5 C. Lithium ions concentrations in zebraﬁsh
were measured by ICP-MS.
2.13. Dark-induced locomotion test
All of the testingwas performed at a temperature of 25 C after 1
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activity assays were performed using a ViewPoint behavior
recording system (Zebrabox) and appropriate software. The eve-
ning before locomotor activity assessment, the larvae were indi-
vidually placed in a 24-well plate. WT and morphant zebraﬁsh
larvae that were immersed in ±1000 ml of E3 medium, 1 mM LiCl or
5 mM LiCl were placed together on each plate. Thirty minutes
before the experiment, the larvae were moved to the behavioral
testing room to adapt to the new conditions. The larvaewere placed
in a Zebrabox for 5 min for acclimation under the neutral light of
50e65 lux and then larva movements were measured under the
following lighting conditions: 10 min under the neutral light or
10min in the dark proceeded by 10min of the bright light (400 lux).
For each experiment three plates were measured in triplicates. The
distance traveled (cm) in the dark per unit time (min) per larva was
calculated and served as a measure of locomotor activity.
2.14. Zebraﬁsh forebrain section preparation and
immunoﬂuorescence
The larvaewere collectedandﬁxed in4%paraformaldehyde inPBS
at 4 C overnight. The following day theywere transferred to PBS that
contained 30% sucrose for equilibration and maintained at 4 C. The
larvae were then embedded in Tissue-Tek O.C.T. (Optimal Cutting
Temperature)compound (Sakura Finetek), kept at80 C for 20 min
for rapid-freezing and stored at20 C. Frozen blockswere coronally
sectioned into 20-mm slices using Leica CM1850 cryostat (Leica
Microsystems). The sections were sealed to the glass slides, washed
three times with PBS and 0.2% Triton X-100 (PBS-T) for 10 min each,
and blocked for 1 h with 1% bovine serum albumin, and 2% normal
donkey serum in 0.5% PBS-T. The sections were then incubated
overnight at 4 C with primary antibodies in humidity chamber. The
following primary antibodies were used: mouse anti-TCF7L2 (1:100,
EMD Millipore) and rabbit anti-b-catenin (1:100, Santa Cruz
Biotechnology). After incubation the sections were washed twice in
PBS for 20 min, and once in 0.2% PBS-T and then incubated with the
secondary antibodies for 2 h. The following secondary antibodies
were used: anti-rabbit and anti-mouse immunoglobulin G coupled
with AlexaFluor 488 and 594. Staining intensity was observed under
Zeiss Axio Imager Z2 LSM700 confocal microscope.
2.15. Statistical analysis
The statistical analyses were performed using t-test, one-way
ANOVA or two-way ANOVA followed by Tukey post hoc test.
Values of p < 0.05 were considered statistically signiﬁcant. The data
were analyzed using GraphPad software. In case of behavioral ex-
periments, the resulting data was initially tested to evaluate dis-
tribution and homogeneity. In all cases the number of animals
tested is denoted by n. Standard deviation is denoted by SD and
standard error of the mean by SEM. Statistical signiﬁcance was
depicted as follows: ns e non signiﬁcant, *p < 0.05, **p < 0.01,
***p < 0.001.
3. Results
3.1. Chronic lithium treatment activates the GSK3/b-catenin
pathway in the forebrain, but b-catenin accumulates in cell nuclei
only in the thalamus
We used a mouse model to determine if the GSK3/b-catenin
pathway is activated in the brain by chronic lithium at
therapeutically-relevant concentrations (Supplementary Fig. S1;
Supplementary Materials and Methods). The treatment was opti-
mized to obtain lithium concentration in the brain and bloodbetween 0.5 mM and 1.5 mM. Mice that exhibited serum lithium
concentration <0.5 mM and >1.5 mM were excluded from further
analyses. The activity of the GSK3/b-catenin pathway was assessed
by the level of active b-catenin (ABC) (Staal et al., 2002), i.e., N-
terminal non-phosphorylated b-catenin, in the thalamus, hippo-
campus, and cortex (the dorsal part). ABC levels increased at least
two-fold in the thalamus and hippocampus when the mice were
administered lithium (Fig. 1A), indicating that in these brain region
GSK3 was inhibited. In the cortex the increase was smaller and was
statistically insigniﬁcant.
The increase in ABC suggested that b-catenin was stabilized and
could translocate into cellular nuclei in the brain. To verify it, we
fractionated tissues of three areas of the forebrain e the thalamus,
hippocampus, and cortex (the dorsal part) e and measured b-cat-
enin levels in cytoplasmic and nucleoplasmic fractions using a
semi-quantitative infrared-based Western blot method. Because
the abundance of membrane-attached b-catenin (b-catenin is a
bifunctional protein that is also involved in cell-cell adhesion;
Valenta et al., 2012) could contaminate other fractions and
contribute to false results, we ﬁrst optimized the fractionation
method using hippocampal homogenates and analyzed the purity
of the fractions using the soluble proteins GAPDH and HSP90,
membrane protein cadherins, and the neuron-speciﬁc nuclear
protein NeuN (Fig. 1B). In the cytosolic fraction, we detected only
the soluble proteins. In the nuclear fraction, we detected the sol-
uble proteins and NeuN. In the membrane fraction, we detected
cadherins, in addition to the soluble proteins and NeuN. Thus,
membranous proteins did not contaminate the cytosolic or nuclear
fractions. Nuclear proteins did not contaminate the cytosolic frac-
tion, and the nuclear fraction was highly enriched in nuclear pro-
teins. We considered this to be satisfactory purity.
We then compared the levels of b-catenin between hippocam-
pal and thalamic fractions from untreated mice (Fig. 1C). b-catenin
was easily detected in the membranes from the thalamus and
hippocampus, and in the cytosol and nucleosol from the thalamus.
In the cytosol and nucleosol from the hippocampus, only a weak b-
catenin signal was detected. These results were supported by our
previous immunohistochemical data, which showed b-catenin
immunoreactivity in neuropils throughout the brain, including the
thalamus and hippocampus, and in neural cell bodies in the entire
thalamus but not hippocampus, cortex or striatum (Nagalski et al.,
2013; Wisniewska et al., 2010).
We then compared the levels of b-catenin between control and
lithium-treated mice in the cytosol and nucleosol of cells from the
thalamus, hippocampus, and cortex. The cytoplasmic and nuclear
levels of b-catenin did not change in the cortex, but the treatment
evoked an approximately two-fold increase in b-catenin in the
cytosolic fraction from the hippocampus and nuclear fraction from
the thalamus (Fig.1D).We also analyzed the subcellular localization
of b-catenin in the brain in lithium-treated mice by immunohisto-
chemistry, to see if b-cateninwas activated in any other areas of the
brain. However, sensitivity of this method did not allow detecting
lowlevels ofb-catenin in the cytoplasmornuclei in areas outside the
thalamus. Thereforewe could only say that apart from the thalamus
massive nuclear translocation of b-catenin did not occur in the brain
in the chronically treated mice (Supplementary Fig. S2).
Concluding, b-cateninwas apparently stabilized in hippocampal
and thalamic cells by chronic lithium treatment, but its accumu-
lationwas observed only in the nuclei of thalamic neurons, where it
could carry out its function as a transcription cofactor.
3.2. Nuclear localization of b-catenin in thalamic neurons is
determined by TCF7L2
We next sought to determine why only thalamic neurons
Fig. 1. Subcellular fractionation of brain tissue and nuclear and cytosolic b-catenin
levels in the brain in control and lithium-treated mice. (A) Western blot analysis of
active b-catenin in total extracts from the thalamus, hippocampus and cortex. GAPDH
staining was used as a loading control. (B) Western blot detection of b-catenin and
markers of the cytosol, membranes, and nuclei in subcellular fractions of the hippo-
campus. b-catenin was observed in the membranes but not in the nuclear or cytosolic
fractions. (C) b-catenin levels in subcellular fractions of the hippocampus and thal-
amus. Hip, hippocampus (mice 1 and 2); Th, thalamus. (D) Western blot analysis of b-
catenin levels in two representative samples of the nuclear and cytosolic fractions from
the thalamus, hippocampus and cortex. NeuN and GAPDH staining was used as a
loading control. Each dot represents one animal. Horizontal lines indicate mean values,
and error bars indicate SD. *p < 0.05, **p < 0.01, ***p < 0.001 (two-tailed t-test).
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previous research showed that TCF7L2 is speciﬁcally expressed in
the thalamus and midbrain (Nagalski et al., 2013), and evidence
from other studies showed that TCF/LEF proteins are able to shift b-
catenin to the nuclei in several cell lines (Huber et al., 1996;Jamieson et al., 2011; Krieghoff et al., 2006). These ﬁndings led us
to hypothesize that TCF7L2 might be involved in the nuclear
localization of b-catenin in the thalamus. To test this hypothesis, we
used primary neuronal cultures as an experimental model.
Thalamic neurons in vitro include a mixture of TCF7L2-positive
and TCF7L2-negative neurons (Misztal et al., 2011). Using immu-
noﬂuorescence analysis, we ﬁrst demonstrated the nuclear locali-
zation of b-catenin in thalamic neurons only in TCF7L2-positive
cells (Fig. 2A). To investigate whether the subcellular localization of
b-catenin in these cells depends on TCF7L2, we silenced the Tcf7l2
gene using RNA interference. We designed three different Tcf7l2-
speciﬁc shRNAs and showed that all of them, but not the control
shRNA, effectively decreased the level of TCF7L2, as revealed by
immunoﬂuorescence analysis. We observed a drop of nuclear b-
catenin staining in the cells in which Tcf7l2 was silenced (Fig. 2B
and C). We next ectopically expressed either TCF7L2 or GFP (as a
control) in cortical cultures. Immunoﬂuorescence revealed a shift of
b-catenin into the nuclei in TCF7L2-expressing cells (Fig. 2D and E).
In contrast, b-catenin localized only to the plasma membrane in
control neurons.
To further investigate the role of TCF7L2 in the nuclear locali-
zation of b-catenin in thalamic neurons, we stabilized the free pool
of b-catenin by treating the cells with the proteasome inhibitor
MG132 for 14 h and then analyzed its subcellular localization
(Fig. 3A and B). In both TCF7L2-positive and TCF7L2-negative
neurons, b-catenin accumulated in the cytoplasm upon MG132
treatment. However, in TCF7L2-negative cells, the ratio of nuclear-
to-cytoplasmic b-catenin levels was 0.5 and did not change upon
MG132 treatment, whereas the ratio was 0.8 and increased to 1.3
when b-catenin was stabilized in TCF7L2-positive cells (Fig. 3C).
Thus, regardless of how high the level of b-catenin was in the
cytoplasm, b-catenin accumulated in the nuclei only in TCF7L2-
positive cells, conﬁrming that the nuclear shift of b-catenin in
thalamic neurons is primarily regulated by TCF7L2 and not by its
stabilization.
3.3. Susceptibility of neurons to the lithium-evoked nuclear
accumulation of b-catenin depends on TCF7L2
To assess whether the effect of lithium treatment also depends
on the presence of TCF7L2, cultured thalamic neurons were treated
for 6 h with 1 mM LiCl, which corresponds to therapeutically
relevant doses in vivo, or 10 mM LiCl that is usually used in a cell
based assays (Kremer et al., 2011) (Fig. 4AeC). In TCF7L2-positive
cells, 1 mM lithium was sufﬁcient to induce the nuclear accumu-
lation of b-catenin in thalamic cells, which was consistent with the
in vivo results (Fig. 1D). In contrast, in TCF7L2-negative neurons, b-
catenin levels increased in the cytoplasm upon 1 mM lithium
treatment, but the shift to the nuclei was observed only when we
increased lithium concentration to 10 mM. This suggests a key role
for TCF7L2 in the susceptibility of thalamic neurons to the lithium-
evoked nuclear accumulation of b-catenin.
We next examined the effects of lithium on b-catenin in cortical
neurons that ectopically expressed TCF7L2 or GFP as a control.
Treatment with 1 mM LiCl did not affect the cytoplasmic or nuclear
levels of b-catenin in control cortical neurons in culture (Fig. 4DeF),
which was consistent with the in vivo ﬁndings for the cortex
(Fig. 1D). However, when TCF7L2 was expressed, b-catenin accu-
mulated in the nucleus, and its level further increased in the
presence of lithium. In this case, 1 mM lithiumwas also sufﬁcient to
evoke the nuclear shift of b-catenin. In both, TCF7L2 expressing and
non-expressing cortical neurons, 10 mM LiCl evoked b-catenin shift
to the nucleus, as expected, though only in the presence of TCF7L2
we observed substantial accumulation of b-catenin. Similar results
were obtained when neurons were treated with the WNT3A
Fig. 2. TCF7L2 drives b-catenin to the nuclei in neurons. (A) Immunoﬂuorescent staining of thalamic and cortical neurons with anti-b-catenin antibody (green), anti-TCF7L2
antibody (orange), and counterstaining with Hoechst (blue). Pink and white arrows point to neurons that are positive and negative for nuclear b-catenin and TCF7L2, respec-
tively. (B) Thalamic neurons were transfected with control or Tcf7l2-speciﬁc shRNA vectors and co-transfected with a GFP vector to visualize transfected neurons (green). The cells
were stained with anti-TCF7L2 antibody (orange), anti-b-catenin antibody (red), and Hoechst (blue). The arrows point to transfected neurons. (C) Scatter plots of b-catenin and
TCF7L2 staining intensities in thalamic neurons. Each dot represents one neuron. (D) Cortical neurons were transduced with either GFP (green) or TCF7L2 adenoviral vectors. The
cells were stained with anti-TCF7L2 antibody (orange), anti-b-catenin antibody (red), and Hoechst (blue). The arrows point to infected neurons. Scale bars ¼ 20 mm. (E) Scatter plots
of b-catenin and TCF7L2 staining intensities in cortical neurons. Each dot represents one neuron.
Fig. 3. Stabilization of b-catenin in thalamic neurons is followed by its nuclear shift only when TCF7L2 is expressed. (A) Thalamic neurons were treated with 10 mMMG132 or
drug vehicle (DMSO; as a control) for 14 h. The cells were stained with anti-TCF7L2 antibody (orange), anti-b-catenin antibody (red), and Hoechst (blue). Scale bar ¼ 10 mm. (B) Two-
scatter plot of intensity values for b-catenin staining in the nucleus and cytoplasm of TCF7L2-positive and -negative thalamic neurons treated with DMSO as a control (black) or
MG132 (white). Each dot represents a single cell. (C) Graph representing the ratio of b-catenin ﬂuorescence values (in arbitrary units) in the nucleus to the values in the cytoplasm.
Each dot represents a single cell. Horizontal lines indicate mean values. ***p < 0.001 (one-way ANOVA followed by Tukey post hoc test). (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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strated that in thalamic neurons b-catenin shifted to the nucleus by
therapeutically-relevant concentrations of lithium, whereascortical neurons were resistant, unless TCF7L2 was ectopically
expressed.
Fig. 4. Sensitivity of neurons to lithium depends on the presence of TCF7L2. (A) Thalamic neurons were treated for 6 h with PBS (control) or 1 or 10 mM LiCl and then ﬁxed and
stained with anti-TCF7L2 antibody (orange), anti-b-catenin antibody (red), and Hoechst (blue). (B) Graph representing the values of b-catenin ﬂuorescence intensity in the nucleus
and cytoplasm of TCF7l2-positive and -negative thalamic neurons under control conditions (black) and upon LiCl treatment: 1 mM (orange) and 10 mM (white). (C) Graph rep-
resenting b-catenin ﬂuorescence values in the nucleus in thalamic neurons. Each dot represents a single cell (at least 65 cells were counted for each condition in two independent
experiments). Horizontal lines indicate mean values. (D) Cortical neurons were transduced with adenoviral vectors that expressed either GFP (left panel) or TCF7L2 (right panel) and
treated for 6 h with PBS (control) or 1 or 10 mM LiCl. GFP-expressing cells are green, and anti-TCF7L2 antibody-stained cells are orange. The cells were stained with anti-b-catenin
antibody (red), and the nuclei were stained with Hoechst (blue). Scale bar ¼ 10 mm. (E) Graph representing the values of b-catenin ﬂuorescence intensity in the nucleus and
cytoplasm of cortical neurons transduced with GFP or a TCF7L2 expression vector under control conditions (black) or upon 1 mM (orange) or 10 mM (white) LiCl treatment. (F)
Graph representing b-catenin ﬂuorescence values in the nucleus in cortical cells. Each dot represents a single cell (at least 70 cells were counted for each condition in two in-
dependent experiments). Horizontal lines indicate mean values. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA followed by Tukey post hoc test).
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treatment depend on the presence of TCF7L2
Lastly, we investigated whether TCF7L2 is involved in the
behavioral response to lithium. Because Tcf7l2/ mice are not
viable because of the defective proliferation of crypt stem cells in
the small intestine (Korinek et al., 1998), we used zebraﬁsh that
subsist on yolk lipids by the ﬁrst 5 days post fertilization (5 dpf)
when the brain is fully formed. In zebraﬁsh, tcf7l2 is expressed in
the thalamus, habenula, and tectum (Young et al., 2002), similar to
observations in mice or rats. Tcf7l2-deﬁcient zebraﬁsh develop
fairly normally up to six weeks (Muncan et al., 2007). Importantly,
the main divisions of the diencephalon (i.e., the thalamus and
habenula) as well as tcf7l2 expression patterns in the zebraﬁsh
brain resemble those in mammals (Nagalski et al., 2013; Young
et al., 2002).
We knocked down tcf7l2 in zebraﬁsh using splice-blocking
morpholino oligonucleotides. We ﬁrst analyzed morpholino efﬁ-
ciency. Western blot revealed a dose-dependent decrease in Tcf7l2
levels in 3 dpf larvae (Supplementary Fig. S4). We decided to use
the 4 ng dose, which was characterized by a high Tcf7l2 depletion
and negligible side effects. Successful Tcf7l2 depletion was
conﬁrmed by immunoﬂuorescence sections from 5 dpf of mor-
phant zebraﬁsh (Fig. 5A). Importantly, inWT zebraﬁsh larvae Tcf7l2
and b-catenin were present in the nuclei of thalamic neurons,
similar to observations in mice. We then examined whether Tcf7l2
inﬂuences the nuclear localization of b-catenin in the zebraﬁsh
thalamus. Immunoﬂuorescent staining revealed b-catenin in cell
nuclei in the thalamus in WT larvae but not in tcf7l2 morphants
(Fig. 5A), which was consistent with our cell culture studies
(Fig. 2B), indicating that Tcf7l2 is needed for the nuclear localization
of b-catenin also in zebraﬁsh.
To investigate whether Tcf7l2 depletion attenuates lithium-
sensitive behavior, we exposed WT and Tcf7l2-deﬁcient zebraﬁsh
to 1 and 5mM LiCl for 2.5 days. The concentrations of lithium in the
zebraﬁsh body at the end of this period were 0.4 mmol/kg and
2 mmol/kg, respectively (measured by ICP-MS). On 5 dpf, larvae
were evaluated for dark-induced locomotor activity. This test has
been previously shown to measure the level of anxiety-like
behavior in zebraﬁsh larvae (Burgess and Granato, 2007;
Steenbergen et al., 2011) and responses to lithium and other
mood stabilizers (Chen et al., 2015; Egan et al., 2009; Irons et al.,
2010; Nery et al., 2014). Locomotor activity was measured as the
distance traveled over a 10 min-period in the dark. Under the
neutral light morphant larvae traveled about twice shorter distance
than WT larvae (Fig. 5B), but sudden darkness induced a three-fold
increase in the locomotion in both morphant and WT larvae. We
found that induced locomotor activity gradually decreased in WT
zebraﬁsh larvae as the concentration of LiCl increased (Fig. 5B),
whereas the average distances traveled by WT larvae that were
immersed in E3 medium or medium supplemented with 5 mM
NaCl were not different. Larvae that were treated with 1 and 5 mMFig. 5. Silencing of tcf7l2 in zebraﬁsh decreases the level of nuclear b-catenin in
thalamic neurons and attenuates the behavioral response to LiCl in zebraﬁsh larvae. (A)
Zebraﬁsh brain slices were stained immunohistochemically with anti-TCF7L2 antibody
(red), anti-b-catenin antibody (green), and counterstained with Hoechst nuclear dye
(blue). TeO e optic tectum, Pr e pretectum, Th e thalamus. (B) tcf7l2 morphant
zebraﬁsh larvae were exposed to LiCl at 2 dpf for 2.5 days, and thereafter dark-induced
locomotion was measured. The chart represents the distance traveled by zebraﬁsh
larvae during 10 min in the dark or under the neutral light under the following con-
ditions e 5 mM NaCl, E3 medium, 1 mM LiCl, and 5 mM LiCl. The colors of bars indicate
different groups of larvae, black e WT, grey e morphants. ****p < 0.0001, *p < 0.05
(two-way ANOVA followed by Tukey post hoc test). Error bars indicate SEM
(n ¼ 23e34).
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tively. In contrast, locomotor activity did not change in morphant
zebraﬁsh, regardless of the LiCl concentration (Fig. 5B). A two-way
ANOVA test showed that the silencing of tcf7l2 had a statistically
signiﬁcant effect on the behavioral response to lithium (p ¼ 0.0027
for the interaction).
4. Discussion
Lithium,which is known to inhibit GSK3, is presumed to activate
b-catenin in the brain when it is taken as a mood stabilizer for the
treatment of BD, but research that may support this hypothesis has
been surprisingly scarce. Our results demonstrated that b-catenin
accumulation in thalamic neurons depends on high levels of
TCF7L2 protein in the thalamus and is potentiated by therapeutic
concentrations of lithium. This TCF7L2-dependent effect inﬂuences
the behavioral response of lithium treatment in zebraﬁsh and
might contribute to the therapeutic effects of this mood stabilizer.
The possibility that GSK3 in the brain can be inhibited by lithium
at therapeutic concentrations has been questioned (Phiel and Klein,
2001). A challenge in addressing this issue is the lack of methods to
detect GSK3 activity in vivo (Hur and Zhou, 2010), and one possi-
bility is to examine the phosphorylation of its targets. In the present
study, we examined changes in the phosphorylation status of the
GSK3 substrate b-catenin. Lithium treatment increased the level of
N-terminal non-phosphorylated b-catenin, also called active b-
catenin, in the thalamus and hippocampus, demonstrating the in-
hibition of GSK3 in these parts of the brain. This active form of b-
catenin is usually assumed to ultimately translocate into the nu-
cleus, but previous research on b-catenin signaling has focused on
undifferentiated cells and cancer cells, which, by nature, readily
respond to canonical Wnt signaling. Our results demonstrate that
such phenomena apparently do not occur in neurons. A shift of b-
catenin into the nucleus was observed only in thalamic cells, what
was further conﬁrmed in primary thalamic and cortical neuronal
cultures that were treated with different concentrations of lithium.
Previous studies reported activation of b-catenin in the hippo-
campus, amygdala and hypothalamus in chronically treated mice
with lithium (Gould et al., 2004; O'Brien et al., 2004). These results,
however, raises some technical questions. In the study of Gould
et al., b-catenin levels were measured in so-called soluble fractions
(Gould et al., 2004), which in fact represented only cytosolic pro-
teins and did not inform about the amount of b-catenin that
actually translocated to the nucleus. In the study of O'Brien et al., b-
catenin activity was determined by an in vivo reporter gene assay in
transgenic mice with a begalactosidase gene driven by b-catenin/
TCF/LEF responsive promoter (O'Brien et al., 2004), but the authors
themselves called their quantiﬁcations preliminary. Moreover,
although TCF/LEF reporter transgenic mice exhibits a correct
readout of b-catenin signaling during development and in cancer,
the reliability of this approach in adult organs, including the brain,
is much less certain (Al Alam et al., 2011; Barolo, 2006). Our results,
showing no effect of lithium on the nuclear shift of b-catenin are
consistent with a recent study (Mills et al., 2014), in which a sta-
bilized form of b-catenin failed to accumulate in the nuclei of
neurons in the hippocampus in transgenic mice.
We demonstrated that this speciﬁc potential of thalamic neu-
rons to accumulate b-catenin in the nuclear compartment depends
on high levels of TCF7L2 protein. This conclusion is based on the
following data on neuronal primary cultures: (i) TCF7L2-positive
thalamic neurons, but not cortical neurons that do not express
endogenous TCF7L2 protein, showed nuclear b-catenin localiza-
tion; (ii) gene silencing of Tcf7l2 by RNA interference in thalamic
neurons effectively decreased the level of nuclear b-catenin,
whereas the ectopic expression of Tcf7l2 in cortical neuronstranslocated b-catenin to the nuclei; and (iii) the stabilization of
free b-catenin through proteasome inhibition in TCF7L2-positive
and TCF7L2-negative thalamic neurons led to nuclear b-catenin
accumulation only in TCF7L2-positive cells. Although, the ability of
TCF/LEF proteins to shift b-catenin to cell nuclei was previously
reported in established cell lines (Huber et al., 1996; Jamieson et al.,
2011; Krieghoff et al., 2006), to our knowledge this is the ﬁrst
demonstration of the physiological signiﬁcance of such a regulatory
mechanism.
As demonstrated herein, the presence of TCF7L2 also pre-
disposes thalamic neurons to the nuclear translocation of b-catenin
upon treatment with a low concentration of lithium (1 mM), which
closely approximates therapeutic levels in humans. In contrast, in
cortical neurons, b-cateninwas not detected in the nucleus unless a
high lithium concentration (10mM)was administered or Tcf7l2was
ectopically expressed. Therefore, the presence of TCF7L2 changes
the threshold for the lithium-evoked nuclear accumulation of b-
catenin. Therapeutic lithium concentrations are sufﬁcient to acti-
vate b-catenin in thalamic neurons, but such concentrations are
below the threshold for other cells. The low level of the b-catenin
destruction complex, which we reported previously (Misztal et al.,
2011), might additionally contribute to the susceptibility of
thalamic neurons to lithium. Cortical neurons that ectopically
expressed TCF7L2 were more prone to b-catenin nuclear trans-
location after lithium treatment than control neurons, but they
were still less sensitive than TCF7L2-positive neurons from the
thalamus, which is consistent with these previous results. There-
fore, we propose that the mechanism of the selective action of
lithium on the thalamus at therapeutically relevant concentrations
involves high levels of TCF7L2 and low levels of GSK3.
To test our hypothesis that TCF7L2-dependent activation of b-
catenin is a part of the therapeutic response to lithium treatment,
we performed a behavioral test in Tcf7l-deﬁcient zebraﬁsh.
Importantly, many recent studies conﬁrmed that zebraﬁsh can be
valuable for analyzing the behavioral effects of lithium (Nery et al.,
2014) and other psychoactive drugs like D-amphetamine (Irons
et al., 2010), ﬂuoxetine (Egan et al., 2009), or lorazepam (Chen
et al., 2015). It was shown that the sudden onset of darkness in-
duces robust locomotor responses in zebraﬁsh larvae, and this ef-
fect can be used to measure anxiety-like behavior (Burgess and
Granato, 2007; Peng et al., 2016; Steenbergen et al., 2011). Our
observation that lithium suppresses locomotor reaction to sudden
darkness in WT larvae is consistent with a previous study (Nery
et al., 2014). However, in the case of tcf7l2 morphant larvae,
lithium exposure did not change the locomotor response. This
result suggests that lithium exerts at least some of its behavioral
effects through the activation of TCF7L2-positive neurons, which
are localized mainly in the thalamus and habenula (Nagalski et al.,
2013).
How the thalamus and habenula could be related to neuropsy-
chiatric disorders? Speciﬁc electrophysiological properties enable
the thalamus to play a major role in directing attention and actively
regulating information transmission to the cortex (Constantinople
and Bruno, 2013; Min, 2010; Mitchell et al., 2014; Saalmann and
Kastner, 2011). Unsurprisingly, the functioning of the thalamo-
cortical loop have been shown to be impaired in schizophrenia,
major depression, and BD (Anticevic et al., 2014a,b; Haijma et al.,
2013; Laje et al., 2010; Miller et al., 2015; Pergola et al., 2015;
Radenbach et al., 2010). It is known that habenular circuits regu-
late fear and anxiety both in mammals and teleost (Facchin et al.,
2015; Heldt and Ressler, 2006; Lee et al., 2010; Mathuru and
Jesuthasan, 2013; Pang et al., 2016; Pobbe and Zangrossi, 2008),
and recent studies reported habenular pathologies in patients with
BD and depression (Lawson et al., 2016; Savitz et al., 2011).
The TCF7L2-dependent effects of lithium in the thalamus might
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psychiatric conditions. Variants of the TCF7L2 gene were associated
with schizophrenia and BD in candidate gene studies (Alkelai et al.,
2012; Hansen et al., 2011; Winham et al., 2014), and de novo mu-
tations in TCF7L2 were found in autistic patients (Iossifov et al.,
2014). Moreover, Tcf7l2 haplo-insufﬁcient mice exhibited anxiety-
like phenotypes in behavioral studies (Savic et al., 2011). Previous
studies from our group suggested that b-catenin, together with
TCF/LEF transcription factors, shapes the intrinsic ﬁring properties
of thalamic neurons by regulating a group of genes that are
involved in neuronal excitability (Wisniewska et al., 2010, 2012). In
zebraﬁsh, Tcf7l2 and Wnt signaling were shown to regulate dif-
ferentiation of neurons in habenula (Beretta et al., 2013; Husken
et al., 2014; Kuan et al., 2015), We speculate that b-catenin activ-
ity that is too low in thalamic (and habenular) neurons can result in
the poor setting and adjustment of response ﬁring modes and
contribute to the pathophysiology of these neuropsychiatric con-
ditions. Lithium, in turn, would restore stability of the thalamo-
cortical and/or habenular system by increasing b-catenin activity
and stabilizing the expression of b-catenin/TCF/LEF-dependent
genes.
Beaulieu et al. proposed another scenario for the therapeutic
action of lithium. According to these authors, lithium may restore
the proper functioning of striatal dopaminergic neurons by inter-
feringwith dopamine D2 receptor-dependent activation of the AKT/
b-arrestin 2/PP2A complex and consequently inhibiting the AKT
target GSK3 (Beaulieu et al., 2004). This possibility was strongly
supported by the resistance of b-arrestin 2 knockout mice to
lithium-induced behavioral changes (Beaulieu et al., 2008) and
antipsychotic effects in mice with GSK3b deletion in D2 receptor-
expressing neurons (Urs et al., 2012). The downstream targets of
dopamine/AKT/GSK3 signaling are currently unknown, but b-cat-
enin is apparently not one of them (Urs et al., 2012). Our hypothesis
of TCF7L2-dependent effects of lithium does not exclude AKT-
mediated lithium's actions on striatal dopaminergic neurons.
These two models instead may be complementary, especially with
regard to other actions of lithium beyond antipsychotic effects.
Both models imply the selective action of lithium on particular
populations of neurons.
Concluding, TCF7L2 potentially mediates molecular effects of
lithium in thalamic and possibly in habenular neurons by facili-
tating the activation of b-catenin, and contributes to behavioral
responses to lithium. Hence, TCF7L2 might provide a link between
lithium's actions, the thalamus and neuropsychiatric conditions. It
also points to TCF7L2 and b-catenin as potential therapeutic targets
in the treatment of mood disorders.
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